Zhao, et al. Cancer Letters 481 (2020) 15–23 Y. Ohsumi, T. Tokuhisa, N. Mizushima

 C. Zhao, et al. Cancer Letters 481 (2020) 15–23 Y. Ohsumi, T. Tokuhisa, N. Mizushima, The role of autophagy during the early of autophagosome-lysosome fusion in human cancer cells, Autophagy 8 (2012) neonatal starvation period, Nature 432 (2004) 1032–1036. 338–349 Diphenylterazine (DTZ). [11] S.H. Noh, S.R. Park, H.K. Yang, H.C. Chung, I.J. Chung, S.W. Kim, H.H. Kim, [30] J. Li, N. Hou, A. Faried, S. Tsutsumi, T. Takeuchi, H. Kuwano, Inhibition of au- J.H. Choi, H.K. Kim, W. Yu, J.I. Lee, D.B. Shin, J. Ji, J.S. Chen, Y. Lim, S. Ha, tophagy by 3-MA enhances the effect of 5-FU-induced apoptosis in colon cancer Y.J. Bang, C.t. investigators, Adjuvant capecitabine plus oxaliplatin for gastric cells, Ann. Surg Oncol. 16 (2009) 761–771. cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, rando- [31] K.N. Dalby, I. Tekedereli, G. Lopez-Berestein, B. Ozpolat, Targeting the prodeath mised phase 3 trial, Lancet Oncol. 15 (2014) 1389–1396. and prosurvival functions of autophagy as novel therapeutic strategies in cancer, [12] M.T. Rosenfeldt, K.M. Ryan, The role of autophagy in tumour development and Autophagy 6 (2010) 322–329. cancer therapy, Expet Rev. Mol. Med. 11 (2009) e36. [32] 

P.Jiang,N.Mizushima,Autophagyandhumandiseases,CellRes.24(2014)69–79. [13] D. Mahalingam, M. Mita, J. Sarantopoulos, L. Wood, R.K. Amaravadi, L.E. Davis, [33] L. Mei, Y. Chen, Z. Wang, J. Wang, J. Wan, C. Yu, X. Liu, W. Li, Synergistic anti- A.C.Mita,T.J.Curiel,C.M.Espitia,S.T.Nawrocki,F.J.Giles,J.S.Carew,Combined tumour effects of tetrandrine and chloroquine combination therapy in human autophagyandHDACinhibition:aphaseIsafety,tolerability,pharmacokinetic,and cancer: a potential antagonistic role for p21, Br. J. Pharmacol. 172 (2015) pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC 2232–2245. inhibitor vorinostat in patients with advanced solid tumors, Autophagy 10 (2014) [34] M.R.Rosenfeld,S.A.Grossman,S.Brem,T.Mikkelsen,D.Wang,S.Piao,L.E.Davis, 1403–1414. P.J. O\'Dwyer, R.K. Amaravadi, Pharmacokinetic analysis and pharmacodynamic [14] R. Rangwala, Y.C. Chang, J. Hu, K.M. Algazy, T.L. Evans, L.A. Fecher, evidence of autophagy inhibition in patients with newly diagnosed glioblastoma L.M. Schuchter, D.A. Torigian, J.T. Panosian, A.B. Troxel, K.S. Tan, D.F. Heitjan, treated on a phase I trial of hydroxychloroquine in combination with adjuvant te- A.M. DeMichele, D.J. Vaughn, M. Redlinger, A. Alavi, J. Kaiser, L. Pontiggia, mozolomide and radiation (ABTC 0603), J. Clin. Oncol. 28 (2010) 3086-3086. L.E. Davis, P.J. O\'Dwyer, R.K. Amaravadi, Combined MTOR and autophagy in- [35] C. Mauvezin, T.P. Neufeld, Bafilomycin A1 disrupts autophagicflux by inhibiting hibition: phase I trial of hydroxychloroquine and temsirolimus in patients with both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autopha- advanced solid tumors and melanoma, Autophagy 10 (2014) 1391–1402. gosome-lysosome fusion, Autophagy 11 (2015) 1437–1438. [15] D.T. Vogl, E.A. Stadtmauer, K.S. Tan, D.F. Heitjan, L.E. Davis, L. Pontiggia, [36] K. Zheng, Y. Li, S. Wang, X. Wang, C. Liao, X. Hu, L. Fan, Q. Kang, Y. Zeng, X. Wu, R. Rangwala, S. Piao, Y.C. Chang, E Oxaliplatin.C. Scott, T.M. Paul, C.W. Nichols, D.L. Porter, H. Wu, J. Zhang, Y. Wang, Z. He, Inhibition of autophagosome-lysosome fusion by J. Kaplan, G. Mallon, J.E. Bradner, R.K. Amaravadi, Combined autophagy and ginsenoside Ro via the ESR2-NCF1-ROS pathway sensitizes esophageal cancer cells proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in to 5-fluorouracil-induced cell death via the CHEK1-mediated DNA damage check- patients with relapsed/refractory myeloma, Autophagy 10 (2014) 1380–1390. point, Autophagy 12 (2016) 1593–1613. [16] N. Darshan, H.K. Manonmani, Prodigiosin and its potential applications, J. Food [37] W.J. Chiu, S.R. Lin, Y.H. Chen, M.J. Tsai, M.K. Leong, C.F. Weng, Prodigiosin- Sci. Technol. 52 (2015) 5393–5407. emerged PI3K/Beclin-1-Independent pathway elicits autophagic cell death in dox- [17] R. Perez-Tomas, M. Vinas, New insights on the antitumoral properties of prodigi- orubicin-sensitive and -resistant lung cancer, J. Clin. Med. 7 (2018). nines, Curr. Med. Chem. 17 (2010) 2222–2231. [38] U. Repnik, V. Stoka, V. Turk, B. Turk, Lysosomes and lysosomal cathepsins in cell [18] V.V. Prabhu, B. Hong, J.E. Allen, S. Zhang, A.R. Lulla, D.T. Dicker, W.S. El-Deiry, death, Biochim. Biophys. Acta 1824 (2012) 22–33. 

 

Small-molecule prodigiosin restores p53 tumor suppressor activity in chemoresis- [39] J. Zhou, S.H. Tan, V. Nicolas, C. Bauvy, N.D. Yang, J. Zhang, Y. Xue, P. Codogno, tant colorectal cancer stem via c-jun-mediated DeltaNp73 inhibition and p73 H.M. Shen, Activation of lysosomal function in the course of autophagy via activation, Canc. Res. 76 (2016) 1989–1999. mTORC1 suppression and autophagosome-lysosome fusion, Cell Res. 23 (2013) [19] Z. Wang, B. Li, L. Zhou, S. Yu, Z. Su, J. Song, Q. Sun, O. Sha, X. Wang, W. Jiang, 508–523. K. Willert, L. Wei, D.A. Carson, D. Lu, Prodigiosin inhibits Wnt/beta-catenin sig- [40] X. Sui, N. Kong, X. Wang, Y. Fang, X. Hu, Y. Xu, W. Chen, K. Wang, D. Li, W. Jin, naling andex###http://www.glpbio.com/simage/GA11233-L-NAME-hydrochloride-5.png####erts anticancer activity in breast cancercells, Proc. Natl.Acad. Sci.U. F. Lou, Y. Zheng, H. Hu, L. Gong, X. Zhou, H. Pan, W. Han, JNK confers 5-fluor- S. A. 113 (2016) 13150–13155. ouracil resistance inp53-deficient andmutant p53-expressing colon cancer cellsby [20] M. Espona-Fiedler, V. Soto-Cerrato, A. Hosseini, J.M. Lizcano, V. Guallar, inducing survival autophagy, Sci. Rep. 4 (2014) 4694. R. Quesada, T. Gao, R. Perez-Tomas, Identification of dual mTORC1 and mTORC2 [41] J. Pan, C. Cheng, S. Verstovsek, Q. Chen, Y. Jin, Q. Cao, The BH3-mimetic GX15- inhibitors in melanoma cells: prodigiosin vs. obatoclax, Biochem. Pharmacol. 83 070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluor- (2012) 489–496. ouracil in esophageal carcinoma cells, Canc. Lett. 293 (2010) 167–174. [21] S.Y. Cheng, N.F. Chen, H.M. Kuo, S.N. Yang, C.S. Sung, P.J. Sung, Z.H. Wen, [42] K. Sasaki, N.H. Tsuno, E. Sunami, G. Tsurita, K. Kawai, Y. Okaji, T. Nishikawa, W.F. Chen, Prodigiosin stimulates endoplasmic reticulum stress and induces au- Y.Shuno,K.Hongo,M.Hiyoshi,M.Kaneko,J.Kitayama,K.Takahashi,H.Nagawa, tophagic cell death in glioblastoma cells, Apoptosis 23 (2018) 314–328. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer [22] C. Zhao, X. Chen, D. Zang, X. Lan, S. Liao, C. Yang, P. Zhang, J. Wu, X. Li, N. Liu, cells, BMC Canc. 10 (2010) 370. Y.Liao,H.Huang,X.Shi,L.Jiang,X.Liu,Z.He,Q.P.Dou,X.Wang,J.Liu,Anovel [43] C.A.Schonewolf,M.Mehta,D.Schiff,H.Wu,B.G.Haffty,V.Karantza,S.K.Jabbour, nickelcomplexworksasaproteasomaldeubiquitinaseinhibitorforcancertherapy, Autophagy inhibition by chloroquine sensitizes HT-29 colorectal cancer cells to Oncogene 35 (2016) 5916–5927. concurrent chemoradiation, World J. Gastrointest. Oncol. 6 (2014) 74–82. [23] X. Shi, X. Chen, X. Li, X. Lan, C. Zhao, S. Liu, H. Huang, N. Liu, S. Liao, W. Song, [44] H.Z. Yang, Y. Ma, Y. Zhou, L.M. Xu, X.J. Chen, W.B. Ding, H.B. Zou, Autophagy P.Zhou,S.Wang,L.Xu,X.Wang,Q.P.Dou,J.Liu,Gambogicacidinducesapoptosis contributes to the enrichment and survival of colorectal cancer stem cells under in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome in- oxaliplatin treatment, Canc. Lett. 361 (2015) 128–136. hibitionandcaspase-dependentBcr-Abldownregulation,Clin.Canc.Res.20(2014) [45] P. Maycotte, S. Aryal, C.T. Cummings, J. Thorburn, M.J. Morgan, A. Thorburn, 151–163. Chloroquine sensitizes breast cancer cells to chemotherapy independent of autop- [24] L.Lu,A.Qin,H.Huang,P.Zhou,C.Zhang,N.Liu,S.Li,G.Wen,C.Zhang,W.Dong, hagy, Autophagy 8 (2012) 200–212. X. Wang, Q.P. Dou, J. Liu, Shikonin extracted from medicinal Chinese herbs exerts [46] P. Chen, X. Luo, P. Nie, B. Wu, W. Xu, X. Shi, H. Chang, B. Li, X. Yu, Z. Zou, CQ anti-inflammatory effect via proteasome inhibition Nifurtimox, Eur. J. Pharmacol. 658 (2011) synergistically sensitizes human colorectal cancer cells to SN-38/CPT-11 through 242–247. lysosomalandmitochondrialapoptoticpathwayviap53-ROScross-talk,FreeRadic. [25] B.J. Bartlett, P. Isakson, J. Lewerenz, H. Sanchez, R.W. Kotzebue, R.C. Cumming, Biol. Med. 104 (2017) 280–297. G.L. Harris, I.P. Nezis, D.R. Schubert, A. Simonsen, K.D. Finley, p62, Ref(2)P and [47] R.J. Molenaar, R.J.S. Coelen, M. Khurshed, E. Roos, M.W.A. Caan, M.E. van Linde, ubiquitinated proteins are conserved markers of neuronal aging, aggregate forma- M.Kouwenhoven,J.A.M.Bramer,J.Bovee,R.A.Mathot,H.J.Klumpen,H.W.M.van tion and progressive autophagic defects, Autophagy 7 (2011) 572–583. Laarhoven, C.J.F. van Noorden, W.P. Vandertop, H. Gelderblom, T.M. van Gulik, [26] T.Kaizuka,H.Morishita,Y.Hama,S.Tsukamoto,T.Matsui,Y.Toyota,A.Kodama, J.W. Wilmink, Study protocol of a phase IB/II clinical trial of metformin and T.Ishihara,T.Mizushima,N.Mizushima,Anautophagicfluxprobethatreleasesan chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours, BMJ internal control, Mol. Cell. 64 (2016) 835–849. Open 7 (2017) e014961. [27] N. Katunuma, Posttranslational processing and modification of cathepsins and cy- [48] J.M. Mulcahy Levy, S. Zahedi, A.M. Griesinger, A. Morin, K.D. Davies, D.L. Aisner, statins, J Signal Transduct (2010) 3753452010. B.K.Kleinschmidt-DeMasters,B.E.Fitzwalter,M.L.Goodall,J.Thorburn,V.Amani, [28] J.M. Levy, J.C. Thompson, A.M. Griesinger, V. Amani, A.M. Donson, D.K. Birks, A.M. Donson, D.K. Birks, D.M. Mirsky, T.C. Hankinson, M.H. Handler, A.L. Green, M.J. Morgan, D.M. Mirsky, M.H. Handler, N.K. Foreman, A. Thorburn, Autophagy R.Vibhakar,N.K.Foreman,A.Thorburn,Autophagyinhibitionovercomesmultiple inhibition improves chemosensitivity in BRAF(V600E) tumors, Canc. Discov. mechanisms of resistance to BRAF inhibition in brain tumors, Elife 6 (2017). 4 (2014) 773–780. [49] P. Pellegrini, A. Strambi, C. Zipoli, M. Hagg-Olofsson, M. Buoncervello, S. Linder, [29] J. Zhou, S.E. Hu, S.H. Tan, R. Cao, Y. Chen, D. Xia, X. Zhu, X.F. Yang, C.N. Ong, A.DeMilito,AcidicextracellularpHneutralizestheautophagy-inhibitingactivityof H.M. Shen, Andrographolide sensitizes cisplatin-induced apoptosis via suppression chloroquine: implications for cancer therapies, Autophagy 10 (2014) 562–571. 23

Comments

Post a Comment

Popular posts from this blog

Zhao, et al. Cancer Letters 481 (2020) 15–23 (caption on next page) 20

 r> C. Zhao, et al. Cancer Letters 481 (2020) 15–23 Fig. 5. The combination of Prodigiosin and 5-Fu inhibits the growth of HCT116 xenografts in nude mice. Nude mice bearing HCT116 xenograft tumors were treated with vehicle, prodigiosin alone (1 mg/kg), 5-Fu alone (30 mg/ kg), or a combination of prodigiosin and 5-Fu twice weekly through i.p. injection for 21 days after inocula- tion with cultured tumor cells. (A) Tumor images and tumor weights are shown.Onday21afterinoculation,the mice were sacrificed, and the tumor tissues were imaged, weighed, and de- tailed. Mean ± SD (n = 5); **, P < 0.01 versus control, prodigiosin or 5-Fu alone. (B) Tumor volume was recorded every three days after treat- ment. Mean ± SD (n = 5); **, P < 0.01 versus control, prodigiosin or 5-Fu alone.  (C) Body weight was recorded every three days during the 21 day of exposure. No sig- nificant differences were detected be- tween the vehicle and other groups: prodigiosin alone CORM-3 , 5-Fu alone
Read more

Nonetheless, some limits remain exist in this [9] M.E.W. Logtenberg

 X.Zhang,etal. Cancer Letters 481 (2020) 32–44 cell extract. Secondly, our data indicated that SSL6 regulates metabo- [8] P.E. Hughes, S. Caenepeel, L.C. Wu, Targeted therapy and checkpoint im- munotherapycombinationsforthetreatmentofcancer,TrendsImmunol.37(2016) lism in HCC cells. Thirdly, SSL6 sensitizes HCC to SFN by down- 462–476. regulating glycolysis. Nonetheless, some limits remain exist in this [9] M.E.W. Logtenberg, J.H.M. Jansen, M. Raaben, M. Toebes, K. Franke, study. For instant, the effects of other metabolism such as lipid meta- A.M. Brandsma, H.L. Matlung, A. Fauster, Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPalpha axis and a target for cancer immunotherapy, bolism on the SFN sensitivity also should be investigated, which may Mainten. Immune Bal. Eff. Targeted Ther. 25 (2019) 612–619. also provide new effective intervention targets. Whether SSL6 could [10] S. Kaur, S.P. Singh, A.G. Elkahloun, W. Wu, M.S. Abu-Asab, D.D. Roberts, CD47- modul
Read more